Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 
Category: Endocrinology | Ophthalmology | Pharmacy | Journal

Back to Journal Articles

Intravitreal Pegaptanib Useful in Diabetic Macular Edema

Last Updated: December 03, 2012.

 

Pegaptanib reduces foveal thickness; improves macular sensitivity, color discrimination

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with diabetes with clinically significant macular edema, treatment with intravitreal pegaptanib sodium (Macugen), which selectively inhibits vascular endothelial growth factor-165 isoforms, is associated with significant morphological and functional changes, according to a study published in the December issue of the British Journal of Clinical Pharmacology.

MONDAY, Dec. 3 (HealthDay News) -- For patients with diabetes with clinically significant macular edema (CME), treatment with intravitreal pegaptanib sodium (Macugen), which selectively inhibits vascular endothelial growth factor-165 isoforms, is associated with significant morphological and functional changes, according to a study published in the December issue of the British Journal of Clinical Pharmacology.

Michele Rinaldi, M.D., of the Seconda Università degli Studi di Napoli in Italy, and colleagues conducted an interventional, longitudinal, non-randomized study involving 30 eyes of 30 patients who were treated with intravitreal pegaptanib sodium for the management of macular edema. Participants were treated with three consecutive injections at baseline, week six, and week 12, and were followed for up to 48 weeks after the injections. Morphological and functional changes were assessed.

Following intravitreal pegaptanib injections, the researchers observed a significant decrease of foveal thickness (FT), with a 56.9 percent mean reduction from baseline. In all patients there was a significant improvement of functional parameters: best-corrected visual acuity (BCVA), macular sensitivity (MS), and color discrimination (CD). There was a significant correlation between FT and BCVA, as well as MS and CD. There were no reports of ocular or systemic adverse events.

"Intravitreal pegaptanib significantly reduced FT, with a concomitant improvement of MS and CD," the authors write. "This association emphasizes the efficacy of intravitreal pegaptanib in the treatment of CME."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: ART Cuts HIV Infection in Serodiscordant Couples in China Next: High Fructose Corn Syrup Availability Linked to Diabetes

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.